Krystal Biotech Stock Earnings Reports

Krystal Biotech reported strong Q1 2026 results driven by continued VYJUVEK global launch momentum and a growing pipeline with multiple upcoming readouts. Q1 net revenue for VYJUVEK was $116.4M (9% sequential growth, 32% YoY), bringing cumulative revenue since launch to >$846M; gross margin was 95% and the company reported its 11th consecutive quarter of positive EPS ($1.91 basic). International launches (Germany, France, Japan, Italy, Spain) contributed $28.9M and early uptake outside the U.S. is encouraging, with >140 DDEB patients prescribed VYJUVEK in Germany, Japan and France and >695 U.S. reimbursement approvals. Management emphasized a “start–stop” treatment cadence as patients move to maintenance and self-administration, and noted insurance switches impacted revenue in the quarter but are largely behind them. The company has cash and investments >$1B and reiterated full-year non-GAAP R&D + SG&A guidance of $175M–$195M. On R&D, Krystal is positioned for an active 12–24 months: 2 registrational readouts expected in 2026 (KB803 for corneal abrasions in DDEB and KB801 for neurotrophic keratitis) and 2 more in 2027, plus additional readouts (repeat-dose KB407 in CF, KB111 in Hailey-Hailey disease, KB707 in NSCLC, KB408 in AATD). The FDA has granted platform technology designations for several programs, which management says streamlines development and compounds program-level advantages. Early-stage registrational strategies include innovative designs leveraging prospectively collected natural history data (e.g., for KB407 in CF with CFF collaboration). Operational priorities: deepen penetration in current international markets, secure reimbursement (notably Germany decision expected H2 2026; France in 2027), expand to Italy and Spain (potential H2 2026 launches pending negotiations), and support enrollment for multiple trials. Management highlighted disciplined capital use and said buybacks would be considered when there is clearer visibility into pipeline and launch timing.